IR@PKUHSC  > 北京大学第二临床医学院  > 妇科
学科主题临床医学
Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center
Zhang Guo; Li Xiao-ping; Liu Bing-jie; Wang Jian-liu; Wang Shi-jun; Cui Heng; Wei Li-hui
关键词Ovarian Cancer Oxaliplatin Drug-resistance Recurrent
刊名CHINESE MEDICAL JOURNAL
2013-12-05
DOI10.3760/cma.j.issn.0366-6999.20130799
126期:23页:4477-4482
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]PEGYLATED LIPOSOMAL DOXORUBICIN ; PHASE-II ; CARCINOMA ; TRIAL
英文摘要

Background Combination paclitaxel and carboplatin is currently a first-line regimen for ovarian cancer. However, many patients develop tumor recurrence or drug resistance to this regimen. The study aims to investigate the effectiveness and safety of an oxaliplatin + epirubicin + ifosfamide regimen for the treatment of recurrent and drug-resistant epithelial ovarian cancer.

Methods A retrospective analysis of 73 patients with recurrent and drug-resistant ovarian cancer was performed; 38 cases of them received oxaliplatin + epirubicin + ifosfamide regimens (IAP group), 35 patients received non-oxaliplatin-based chemotherapy regimens (control group). The therapeutic effects and side effects of the oxaliplatin + epirubicin + ifosfamide regimen were analyzed and summarized. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare progression-free and overall survival between the two groups.

Results Of the 38 patients in the IAP group, 14 patients (36.84%) achieved complete remission, 12 (31.58%) achieved partial remission, 2 (5.26%) achieved stable disease and 10 (26.32%) developed progressive disease. The overall effective rate (complete or partial remission) of the IAP regime was 68.42%. While, of the 35 patients in the control group, 12 patients (34.29%) achieved complete remission, 3 (8.57%) achieved partial remission, 5 (14.29%) achieved stable disease and 15 (42.86%) developed progressive disease. The overall effective rate was 42.86%, which was lower than that in the IAP group (P=0.035, chi(2)=4.836). Progression-free survival was 9.5 months (0-64 months) in the IAP group vs. 3 months (0-74 months) in the non-oxaliplatin group (P=0.014 by Kaplan-Meier survival curves; HR=2.260; 95%CI 1.117-4.573; P=0.023 by Cox proportional hazards regression). Median overall survival was 46 months (9-124 months) in the IAP group vs. 35 months (9-108 months) in non-oxaliplatin group (P=0.018 by Kaplan-Meier survival curves; HR=2.272; 95%CI 1.123-4.598; P=0.022 by Cox proportional hazards regression). In IAP group, 15.79% (6/38) of the patients suffered grade III-IV bone marrow arrest. The main non-hematological side effects of the IAP regimen included nausea and vomiting (21.05%, 8/38), peripheral neurotoxicity (15.79%, 6/38) and hepatic or renal lesions (2.63%, 1/38). The main side effects of the two chemotherapy regimens showed no statistical difference.

Conclusion The oxaliplatin-based IAP regimen is potentially effective for salvage chemotherapy in patients with recurrent and drug-resistant ovarian cancer, with a better therapeutic effect and tolerable side effects.

语种英语
WOS记录号WOS:000329084100014
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54356
专题北京大学第二临床医学院_妇科
作者单位Peking Univ Peoples Hosp, Dept Gynecol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Zhang Guo,Li Xiao-ping,Liu Bing-jie,et al. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center[J]. CHINESE MEDICAL JOURNAL,2013,126(23):4477-4482.
APA Zhang Guo.,Li Xiao-ping.,Liu Bing-jie.,Wang Jian-liu.,Wang Shi-jun.,...&Wei Li-hui.(2013).Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.CHINESE MEDICAL JOURNAL,126(23),4477-4482.
MLA Zhang Guo,et al."Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center".CHINESE MEDICAL JOURNAL 126.23(2013):4477-4482.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang Guo]的文章
[Li Xiao-ping]的文章
[Liu Bing-jie]的文章
百度学术
百度学术中相似的文章
[Zhang Guo]的文章
[Li Xiao-ping]的文章
[Liu Bing-jie]的文章
必应学术
必应学术中相似的文章
[Zhang Guo]的文章
[Li Xiao-ping]的文章
[Liu Bing-jie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。